Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 1,898 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Effect of Drug Clear all

Conditions: Low Back Pain
Interventions: PPP treatment, PRP treatment, PRP and PL Combo treatment; Biological
Lead sponsor: Regenexx, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Broomfield, Colorado • Lone Tree, Colorado

Conditions: Obesity
Interventions: Placebo, CP-945,598, CP-945,598 Treatment B; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 975 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 43
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 37 more

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: intraconazole, Rifampin, EDP 305; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Muscle Weakness, Myalgia, Side Effects of Statins
Interventions: Coenzyme q 10, placebo; Drug
Lead sponsor: Richard Deichmann, MD; Other
Eligibility: 50 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Marijuana Use, Opioid Use
Interventions: Marijuana, Opioid; Drug
Lead sponsor: Shanna Babalonis, PhD; Other
Eligibility: 18 Years to 50 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: HIV Infections
Interventions: Lamivudine/Zidovudine, HIV-1 Immunogen, Nelfinavir mesylate; Drug · Biological
Lead sponsor: Agouron Pharmaceuticals; Industry
Eligibility: 13 Years and older
Enrollment: 688 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Diego, California

Conditions: Post-operative Pain, Colon Cancer, Diverticulitis
Interventions: Bupivacaine, Bupivacaine liposome suspension; Drug
Lead sponsor: Des Moines University; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Des Moines, Iowa

Conditions: Drug-drug Interaction
Interventions: Omeprazole 40 MG, Famotidine 40 mg, Telotristat ethyl 250 mg; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Alzheimer Disease, Healthy Volunteers
Interventions: TAK-071, Donepezil, TAK-071 Placebo, Donepezil Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 179 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy, Safety Issues
Interventions: Cannabinol, Placebo; Dietary Supplement · Other
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Cancer
Interventions: pazopanib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: New Brunswick, New Jersey • Greenville, South Carolina

Conditions: Epilepsy
Interventions: observation of VNS stimulation effects; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Malignancy, Immune Related Adverse Events
Interventions: Informatics system for eligibility monitoring, Standard eligibility monitoring; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Dysbiosis
Interventions: Cranberry beverage, Placebo beverage; Other
Lead sponsor: Iowa State University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Ames, Iowa

Conditions: Anaplastic Large Cell Lymphoma
Interventions: Cyclophosphamide, Doxorubicin hydrochloride, vincristine sulfate, prednisone, SGN-30; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cannabis, Alcohol Effect, Driving Under the Influence of Alcohol and Other Drugs
Interventions: Active delta-9-THC, Placebo, Active Ethanol; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Glaucoma
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 30 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Autism, Autistic Disorder, Child Development Disorders, Pervasive, Gastrointestinal Diseases, Signs and Symptoms, Digestive
Interventions: Oralgam (human immunoglobulin); Drug
Lead sponsor: PediaMed Pharmaceuticals; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 22
States / cities: Phoenix, Arizona • Sacramento, California • Gainesville, Florida + 17 more

Conditions: Endometrial Cancer
Interventions: BNT323/DB-1303, Doxorubicin, Paclitaxel, Docetaxel; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 22
States / cities: Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 19 more

Conditions: Healthy Volunteers
Interventions: Branebrutinib, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Sacroiliac; Backache, Pain, Back
Interventions: PremierMaxCB®-Platinum (CFL001);; Biological
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 90 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Healthy Volunteers
Interventions: TAK-915 suspension, Midazolam, Placebo, TAK-915 tablet; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Type 2 Diabetes
Interventions: Dapagliflozin, Placebo-matching dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 2,996 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 164
States / cities: Birmingham, Alabama • Mobile, Alabama • Ozark, Alabama + 124 more

Conditions: HIV Infections, Hepatitis C
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 42
States / cities: Los Angeles, California • Menlo Park, California • San Diego, California + 27 more

Search by objective public record fields.

A Trial Comparing Three Orthobiologic Therapies on Atrophied Multifidus Muscles in Patients With Low Back Pain

A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients

Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers

Coenzyme Q10 in Older Athletes Treated With Statin Medications

Reinforcing Effects of Marijuana and Opioids

Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)

The Effect of Exparel on Post Operative Pain and Narcotic Use After Colon Surgery

A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

Assessing the Effects of a Cannabidiol Derived From Hemp Supplement in Healthy Adults

VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK

Assessment of Effect of Vagal Nerve Stimulator (VNS) on Electrocorticograms Recorded by Responsive Neurostimulator (RNS) in Patients With Drug Resistant Epilepsy

Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository

Prebiotic Effects of a Polyphenol-rich Food Product

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition

Aqueous Suppressant Versus Aqueous Outflow on Ocular Blood Flow

Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy Participants

A Study Assessing the Safety of Cord Blood Product in Sacroiliac Joint Syndrome (SIJ)

Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker

A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection